Metraipolis › archive › dc_5264c7dda1ea
Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study — Europe PMC PMID:42396447
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42396447
- DOI
- 10.3389/fimmu.2026.1857350
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-19T08:12:03.904Z
- SHA-256 of the archived text
fd681b231ac0bdaf22f0478858413c67a163f7c398180d6a71f3c46de35b81ee- Stable URL of this page
https://metraipolis.com/documento/dc_5264c7dda1ea
How to cite
Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study — Europe PMC PMID:42396447 — Europe PMC (en), https://europepmc.org/article/MED/42396447 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5264c7dda1ea (Metraipolis archive dc_5264c7dda1ea, sha256 fd681b231ac0bdaf22f0478858413c67a163f7c398180d6a71f3c46de35b81ee)
BibTeX
@misc{dc5264c7dda1ea,
title = {Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study — Europe PMC PMID:42396447},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42396447},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5264c7dda1ea; sha256 fd681b231ac0bdaf22f0478858413c67a163f7c398180d6a71f3c46de35b81ee},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42396447. Agents can read the archived copy with the MCP tool read_document.